Daratumumab Shows Clinical Benefit in Combination With Standard of Care in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
CASSIOPEIA is the first phase III study to evaluate daratumumab in that setting
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
Population-level Impact of HPV Vaccination
Effectiveness of HPV vaccines in real-world settings based on up to 8 years of post-vaccination follow-up data
EMA Recommends Extension of Indications for Ramucirumab
New indication concerns monotherapy for advanced or unresectable hepatocellular carcinoma with AFP ≥ 400 ng/ml
EMA Recommends Extension of Indications for Atezolizumab
New indication concerns combination treatment with nab-paclitaxel for unresectable locally advanced or metastatic TNBC
Molecular Profiling in Routine Practice for Advanced Cancers
Limited clinical benefit achieved in the ProfiLER study
Japan Becomes the First Country to Approve Entrectinib
Tumour-agnostic medicine is approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Clinical Utility of Neoadjuvant Immune Checkpoint Inhibitors in Resectable NSCLC Remains Unknown
More research is also needed to identify optimal biomarkers
Which Neoadjuvant Treatment Strategy for High-Risk Resectable Melanoma?
NeoCombi and OpACIN-neo point to a critical assessment of patterns of relapse to two neoadjuvant treatment approaches
BLU-667 in RET-driven NSCLC and Thyroid Cancer
An update on the registration-enabling ARROW study
FDA Approves Pembrolizumab for Metastatic Small Cell Lung Cancer
Efficacy was investigated in patients who had disease progression on or after two or more prior lines of therapy and enrolled in the KEYNOTE-158 Cohort G or KEYNOTE-028 Cohort C1
Five-Year Survival Data in Advanced NSCLC Treated with Pembrolizumab
Latest data from KEYNOTE-001 study provide the longest efficacy/safety follow-up in this setting
Five-Year Outcomes with Combination Targeted Therapy in Metastatic Melanoma
Long terms outcomes in BRAF V600-mutated unresectable or metastatic melanoma